Welcome to our dedicated page for Bio-Techne news (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne stock.
Bio-Techne Corporation (NASDAQ: TECH) provides this centralized hub for investors and industry professionals tracking developments in life sciences innovation. Access official press releases, financial disclosures, and strategic updates from the global leader in bioactive reagents and diagnostic solutions.
This resource delivers timely updates on earnings results, product launches, and strategic collaborations critical to understanding the company's position in biotechnology markets. Users will find announcements related to protein analysis advancements, spatial biology innovations, and global distribution partnerships.
All content is sourced directly from Bio-Techne's corporate communications, ensuring accuracy for those monitoring investment opportunities or industry trends. Bookmark this page for efficient access to material developments affecting TECH's market performance and scientific impact.
Bio-Techne Corporation (NASDAQ:TECH) reported strong financial results for Q3 FY2021, with organic revenue growth of 22% to $243.6 million. GAAP EPS increased to $1.12, up from $0.92 last year, while adjusted EPS rose to $1.79 from $1.39. The company achieved a remarkable adjusted operating margin of 40.1%, reflecting effective cost management and higher demand across its segments. Notably, Protein Sciences experienced organic growth of 24%, while Diagnostics and Genomics grew by 17%. Bio-Techne also enhanced its Diagnostics segment through the acquisition of Asuragen.
Bio-Techne Corporation (NASDAQ: TECH) and 908 Devices (NASDAQ: MASS) have announced a collaboration to develop a comprehensive protein characterization solution. This integration will combine Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip device. The partnership aims to streamline workflow for scientists, enhancing drug development efficiency via in-depth analysis of biotherapeutics. The combination of these technologies is expected to deliver faster commercialization, leveraging high-resolution separation techniques and mass spectrometry capabilities.
908 Devices (NASDAQ: MASS) and Bio-Techne Corporation (NASDAQ: TECH) announced a collaboration to enhance protein characterization workflows. This partnership combines Bio-Techne's Maurice icIEF separation instrument with 908 Devices' ZipChip technology, streamlining the analysis process for biotherapeutics. The integrated solution aims to improve drug development efficiency by providing rapid, high-resolution separation techniques and mass spectrometry identification, catering to the growing biopharmaceutical market.
Bio-Techne Corporation (NASDAQ:TECH) announced the launch of DNAscope Assays, expanding their Advanced Cell Diagnostics RNAscope technology. This new chromogenic DNA in situ hybridization (ISH) technology allows for single-cell resolution to visualize DNA aberrations in FFPE tissues using standard bright-field microscopes. DNAscope provides advantages over traditional FISH techniques, offering precise detection of small genomic regions. Kim Kelderman, President of Diagnostics and Genomics Segment, stated that this launch strengthens their position in spatial genomic analysis, enhancing multi-omic capabilities for faster decision-making.
Bio-Techne Corporation (NASDAQ: TECH) announced the rebranding of its Pharma Assay Services to Professional Assay Services, aimed at enhancing accessibility for global academic and clinical institutions. The updated services include in situ hybridization (ISH) gene expression analysis, tissue procurement, and custom assay development. Supported by a team of experts, these services comply with Good Clinical Laboratory Practices (GCLP). Kim Kelderman, President of Diagnostics and Genomics, emphasized the commitment to facilitate faster drug development timelines while maintaining cost efficiency.
Bio-Techne Corporation (NASDAQ: TECH) has entered a licensing agreement with Xencor, Inc. for the use of its proprietary antibody in developing innovative cancer therapeutics. This marks Bio-Techne's third collaboration with Xencor, emphasizing their role in the immuno-oncology field. The agreement allows Xencor to utilize Bio-Techne's extensive antibody portfolio alongside its XmAb® protein engineering technology, aimed at creating bispecific antibodies and engineered cytokines. Bio-Techne's commitment to the biopharma industry continues to grow through these strategic partnerships.
Bio-Techne Corporation (NASDAQ:TECH) has launched Abby, an advanced chemiluminescence system designed to automate the traditional Western blotting process. Abby features picogram-level sensitivity and the innovative RePlex™ technology, enabling sequential immunoassays. Additionally, the new Compass software enhances data analysis efficiency. The company also announced the upcoming Stellar™ NIR and IR modules for Jess™, which aim to elevate fluorescence Western blotting sensitivity. Bio-Techne emphasizes that these products contribute to faster, more reproducible results, essential for modern research environments.
Bio-Techne Corporation (NASDAQ: TECH) announced the completion of its acquisition of Asuragen, Inc., valued at $215 million in cash with up to $105 million contingent on future milestones. This acquisition enhances Bio-Techne's portfolio with advanced molecular diagnostic products, including genetic screening and oncology testing kits. It also provides a GMP-compliant manufacturing facility and a CLIA-certified laboratory. The company anticipates significant growth synergies from this deal, particularly in commercializing molecular products for broader market adoption.
Bio-Techne Corporation (NASDAQ: TECH) will host a conference call and webcast on May 6, 2021, at 8:00 a.m. CDT to discuss its third quarter 2021 financial results. Interested participants can join by dialing 1-877-407-9208 or accessing the webcast at public.viavid.com. A recorded replay will be available from 11:00 a.m. CDT on May 6 until 11:00 p.m. CDT on June 6, 2021. In fiscal 2020, Bio-Techne generated approximately $739 million in net sales.
FAQ
What is the current stock price of Bio-Techne (TECH)?
What is the market cap of Bio-Techne (TECH)?
